Categories: Market Research

Global Anti-Cancer MAbS Market Size and Forecast 2024-2033|Amgen Inc., Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC

The Anti-Cancer MAbS by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Anti-Cancer MAbS Market:

https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report

According to The Business Research Company’s Anti-Cancer MAbS, The anti-cancer mabs market size has grown rapidly in recent years. It will grow from $59.98 billion in 2023 to $66.1 billion in 2024 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to increasing cancer incidence rates, growing understanding of cancer biology, rise in personalized medicine approaches, increased investment in research and development, growing patient awareness and demand.

The anti-cancer mabs market size is expected to see strong growth in the next few years. It will grow to $95.99 billion in 2028 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to advancements in immunotherapy, increasing adoption of combination therapies, emergence of next-generation mabs, global efforts to address cancer burden, expansion of patient access programs.. Major trends in the forecast period include innovations in drug delivery technologies, integration of artificial intelligence in drug discovery, collaborations and partnerships in the pharma industry, advancements in biotechnology, car-t cell therapies.

The increasing prevalence of cancer across the globe is expected to propel the growth of the anticancer MABs market going forward. Cancer refers to the disease that is a chronic disease that lasts for a longer time. Anticancer monoclonal antibodies (mAbs) are specifically designed to bind specific proteins found on cancerous cells as well as they use genetically engineered versions of the immune system’s own antibodies to target and destroy cancer cells, as a result, increasing the prevalence of cancer increases the demand for anticancer MABs market. For instance, in January 2022, according to PubMed, a US-based biomedical and life sciences journal, it is estimated that around 1.9 million new cancer cases are expected to be diagnosed globally, with 609,360 cancer deaths in the United States. Therefore, increasing the prevalence of cancer across the globe is propelling the growth of the anticancer mAbs market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=9041&type=smp

The anti-cancer mabs market covered in this report is segmented –

1) By Type: Murine Antibodies, Chimeric Antibodies, Humanized Antibodies, Other Types

2) By Application: Blood Cancer, Breast Cancer, Lung Cancer, Melanoma, Colorectal Cancer, Liver Cancer, Other Applications

3) By End User: Hospitals, Research Institutes, Other End Users

Product innovations are a key trend gaining popularity in the anticancer mAbs market. Major companies operating in the anticancer mAbs market are introducing more effective and targeted cancer treatments, such as mAbs drugs to strengthen their position in the market. For instance, in May 2022, Roche Holding AG, a Switzerland-based pharmaceutical company launched PHESGO. PHESGO (pertuzumab, trastuzumab, and hyaluronidase-zzxf) is a unique monoclonal antibody (mAb) combination treatment for HER2-positive early breast cancer. It is a subcutaneous (under the skin) injection that combines the two mAbs pertuzumab and trastuzumab with the enzyme hyaluronidase. The addition of hyaluronidase, an enzyme that helps to increase the absorption of the mAbs, allows the treatment to be given subcutaneously rather than intravenously.

The anti-cancer mabs market report table of contents includes:

1. Executive Summary

2. Anti-Cancer MAbS Market Characteristics

3. Anti-Cancer MAbS Market Trends And Strategies

4. Anti-Cancer MAbS Market – Macro Economic Scenario

5. Global Anti-Cancer MAbS Market Size and Growth

26. South America Anti-Cancer MAbS Market

27. Brazil Anti-Cancer MAbS Market

28. Middle East Anti-Cancer MAbS Market

29. Africa Anti-Cancer MAbS Market

30. Anti-Cancer MAbS Market Competitive Landscape And Company Profiles

Top Major Players: